72.94 USD
+0.74
1.02%
At close Dec 20, 4:00 PM EST
After hours
72.94
+0.00
0.00%
1 day
1.02%
5 days
3.01%
1 month
-9.43%
3 months
-18.94%
6 months
-16.44%
Year to date
-12.56%
1 year
-11.11%
5 years
-2.94%
10 years
34.20%
 

About: Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Employees: 41,100

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

33% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 40

23% more repeat investments, than reductions

Existing positions increased: 142 | Existing positions reduced: 115

11% more call options, than puts

Call options by funds: $1.11M | Put options by funds: $996K

5% more capital invested

Capital invested by funds: $5.11B [Q2] → $5.39B (+$280M) [Q3]

4% more funds holding

Funds holding: 352 [Q2] → 365 (+13) [Q3]

2.9% less ownership

Funds ownership: 98.03% [Q2] → 95.13% (-2.9%) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for MMS.

Financial journalist opinion

Based on 10 articles about MMS published over the past 30 days

Positive
Zacks Investment Research
1 week ago
Is Maximus (MMS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Maximus (MMS) Stock Undervalued Right Now?
Negative
Zacks Investment Research
1 week ago
Maximus (MMS) Loses -21.83% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Maximus (MMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Maximus (MMS) Loses -21.83% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Neutral
Business Wire
1 week ago
Maximus Completes Divestiture of Australia and South Korea in Outside the U.S. Segment
TYSONS, Va.--(BUSINESS WIRE)--Maximus divests all operations in Australia and South Korea, which were reported under the Outside the U.S. segment, to Angus Knight.
Maximus Completes Divestiture of Australia and South Korea in Outside the U.S. Segment
Positive
Zacks Investment Research
2 weeks ago
Here's Why Maximus Stock is a Great Pick for You Right Now
MMS stock is benefiting from business process expansion on the back of strategic buyouts. Consistent dividend payments boost investor confidence.
Here's Why Maximus Stock is a Great Pick for You Right Now
Neutral
Business Wire
2 weeks ago
Maximus Earns URAC Accreditation for Health Utilization Management in Clinical Reviews
TYSONS, Va.--(BUSINESS WIRE)--Maximus has again earned URAC full accreditation for Health Utilization Management for clinical reviews.
Maximus Earns URAC Accreditation for Health Utilization Management in Clinical Reviews
Positive
Zacks Investment Research
3 weeks ago
Should Value Investors Buy Maximus (MMS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Maximus (MMS) Stock?
Positive
Zacks Investment Research
3 weeks ago
Down -16.15% in 4 Weeks, Here's Why Maximus (MMS) Looks Ripe for a Turnaround
Maximus (MMS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -16.15% in 4 Weeks, Here's Why Maximus (MMS) Looks Ripe for a Turnaround
Neutral
Seeking Alpha
4 weeks ago
Maximus, Inc. (MMS) Q4 2024 Earnings Call Transcript
Maximus, Inc. (NYSE:MMS ) Q4 2024 Earnings Call Transcript November 21, 2024 9:00 AM ET Company Participants Jessica Batt - VP of IR and ESG Bruce Caswell - President and CEO David Mutryn - CFO Conference Call Participants Charlie Strauzer - CJS Securities Operator Greetings, and welcome to the Maximus Fiscal 2024 Fourth Quarter and Year End Earnings Conference Call. At this time, all participants are on a listen-only mode.
Maximus, Inc. (MMS) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
4 weeks ago
Maximus' Q4 Revenues Surpass Estimates, Earnings Miss
Maximus' fourth-quarter fiscal 2024 earnings and revenues increase on a year-over-year basis.
Maximus' Q4 Revenues Surpass Estimates, Earnings Miss
Positive
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Maximus (MMS) Q4 Earnings
The headline numbers for Maximus (MMS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About Maximus (MMS) Q4 Earnings
Charts implemented using Lightweight Charts™